- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Global Human Capital and Compliance
- Investment Funds and Asset Management
- Leveraged Finance
- Mergers and Acquisitions
- Middle East and Islamic Finance and Investment
- Private Credit & Special Situations Investing
- Private Equity
- Public Companies
- Real Estate
- Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Construction and Engineering Disputes
- Corporate and Securities Litigation
- E-Discovery
- Intellectual Property
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- back
- Industries / Issues
- Automotive, Transportation and Mobility
- Energy
- Financial Services
- Food and Beverage
- Franchise and Hospitality
- Higher Education
- Life Sciences and Healthcare
- Technology
- #MeToo
- Buy American
- COVID-19 Vaccine Rollout
- Coronavirus
- Crisis Practice
- Environmental Agenda
- Focus on Women's Health
- Special Purpose Acquisition Companies (SPACs)
- The New Administration: Enforcement and Legislative Impact
- Careers
- News & Insights
- About
- Languages
Insights 67 results
Client Alert
November 9, 2021
A Magic Mixing Cauldron for the 21st Century: FDA’s new guidances on using real-world data in regulatory decision-making
Client Alert
October 1, 2021
Considering a Move to Texas? Here’s What You Need to Know About Patent Litigation
Client Alert
Client Alert
June 8, 2021
Are States Making COVID-19 Telehealth Emergency Measures Permanent?
Client Alert
May 5, 2021
Diversity and Inclusion – An Asia-Pacific Perspective
Client Alert
April 20, 2021
FDA Reverses HHS Exemption of Class I and Class II Medical Devices from Section 510(k)
Client Alert
April 16, 2021
Early Trends Provide Guidance for Required 10-K Human Capital Disclosures
Client Alert
March 18, 2021
Prosecutors Using FIRREA to Investigate Pandemic Conduct
Client Alert
March 4, 2021
Communicating with Employees through their Personal Devices
Client Alert
February 26, 2021
Tracking Employee Vaccinations Globally: Can You Obtain The COVID-19 Vaccination Status Of Your Employees Everywhere?
Client Alert
February 23, 2021
Mandatory Employee Vaccinations Globally: Can You Require Your Employees To Get The COVID-19 Vaccine Everywhere?
Client Alert
February 5, 2021
FDA Appoints Renowned Cybersecurity Researcher to Head Agency's Medical Device Cybersecurity Efforts